Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that Forsythiaside A improved survival and reduced neurological deficits in rats with cerebral ischemic injury, potentially through activating Nrf2 and reducing ER stress pathways.

This case report describes a 50-year-old woman with frontal fibrosing alopecia who showed no improvement despite multiple treatments, including intralesional triamcinolone and topical glucocorticoids.

This letter discusses congenital triangular alopecia (TTA), a non-scarring hair loss condition often seen in children, without reporting new clinical findings.

In this case study, an 18-year-old woman's triangular alopecic patch diagnosed as temporal triangular alopecia was considered non-progressive and had no impact on her quality of life, so no treatment was initiated.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

Fusarium sp. strain K-23 helps Arabidopsis plants grow better in salty soil by promoting root hair growth.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This study suggests that fusaric acid at nontoxic concentrations may activate signal transduction in plants which could aid in the plant-defense responses against Fusarium spp.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

This review highlights available treatments for frontal fibrosing alopecia, noting that 5-alpha reductase inhibitors, intralesional steroids, and hydroxychloroquine currently have the most evidence supporting their use, while other treatments show variable results and require further study.

This study found that skin exposure to toluene diisocyanate in mice creates immune-recognition reservoirs in the skin's stratum corneum and hair follicles, potentially leading to sensitization and allergic reactions.

This study found a high prevalence of beard and eyebrow alopecia in male patients with frontal fibrosing alopecia, and suggests a potential link between hormonal imbalances and the condition.

This review discusses traction alopecia in individuals with Afro-textured hair and emphasizes the importance of education to prevent this condition, but it reports no new clinical results.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

This review discusses the free hormone hypothesis for measuring "free" testosterone and critiques its theoretical basis and clinical application, noting it lacks critical empirical testing and has inconsistent utility in assessing androgen status.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.

This article notes slow progression and spontaneous stabilization in untreated cases of a specific scarring alopecia and reports no new results; the authors call for randomized trials to confirm the treatment's benefit.

This case study reports successful treatment of frontal fibrosing alopecia with daily 2.5mg finasteride in a 77-year-old woman.

This study identifies specific trichoscopic features such as empty follicles and perifollicular erythema in Caucasians with frontal fibrosing alopecia, which may assist in diagnosis and monitoring, but stresses the need for further research due to limited demographic data.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

This study observed that abnormal hormone levels were associated with lower disease activity in frontal fibrosing alopecia, while thyroid disorders were a common comorbidity among the affected population.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.